Clinical Trials
33 trialsTesting Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NRG Oncology
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
Second Affiliated Hospital of Nanchang University
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Guangdong Association of Clinical Trials
Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer
Mayo Clinic
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
Guangzhou University of Traditional Chinese Medicine
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Taipei Veterans General Hospital, Taiwan
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Shanghai Chest Hospital
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
Guangzhou Medical University
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Tianjin Medical University Cancer Institute and Hospital
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
University of Washington
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
City of Hope Medical Center
IT-IO
University of Zurich
AI-Based Ultrasound Prediction Model for Intracranial Pressure and Prognosis in Lung Cancer Patients With Leptomeningeal Metastasis: A Dual-Center Study
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
FLAME-1
Henan Cancer Hospital
CLM-tree datab
Guangzhou Medical University
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
Henan Cancer Hospital
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
British Columbia Cancer Agency
Better Brain
Sun Yat-sen University
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
Xiangya Hospital of Central South University
FORESEE
Biocept, Inc.
Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
First Affiliated Hospital of Zhejiang University
Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles
Three Gorges Hospital of Chongqing University
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Kadmon Corporation, LLC
ATTRACT
Second Affiliated Hospital of Nanchang University
Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer
Hebei Medical University
BLOOM
AstraZeneca
OWBLM
Second Affiliated Hospital of Nanchang University
OWONBNSCLCLM
Second Affiliated Hospital of Nanchang University
ctDNA
Sun Yat-sen University
A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis
Peking Union Medical College Hospital
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
Clinical Research Center for Solid Tumor, Korea